Search This Blog

Tuesday, November 17, 2026

Merck ends Ph 3 program for leukemia treatment

 Merck discontinued its Phase 3 BELLWAVE trials and broader nemtabrutinib development program after review found the treatment’s benefits may not outweigh its risks.

https://finviz.com/stock?t=MRK&p=d

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.